| Schedule of Segment Reporting Expenses |
The table below shows a reconciliation of the Company’s net loss, including the significant expense categories regularly provided to and reviewed by the CODM, as computed under U.S. GAAP to the Company’s total net loss in the statements of operations (in thousands). | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | | 2025 | | 2024 | | 2025 | | 2024 | | Operating expenses: | | | | | | | | | | Bexotegrast - clinical trial and third party contracting costs | | 13,359 | | | 26,360 | | | 34,948 | | | 43,577 | | | Employee-related expenses - research and development (excluding stock-based compensation) | | 10,344 | | | 8,381 | | | 20,830 | | | 17,519 | | | General and administrative costs (excluding stock-based compensation) | | 8,947 | | | 8,476 | | | 19,236 | | | 17,126 | | | Other segment items | | 12,942 | | | 17,422 | | | 29,513 | | | 34,809 | | | Segment loss | | 45,592 | | | 60,639 | | | 104,527 | | | 113,031 | | | Reconciliation of segment loss | | | | | | | | | | Interest and other (income) expense, net | | (3,101) | | | (5,653) | | | (6,669) | | | (11,535) | | | Interest expense | | 809 | | | 868 | | | 1,608 | | | 1,313 | | | Net loss | | $ | 43,300 | | | $ | 55,854 | | | $ | 99,466 | | | $ | 102,809 | |
|